Latest news with #JasonCarroll
Yahoo
4 hours ago
- Politics
- Yahoo
LAPD Briefly Detains CNN Reporter During Live Coverage of Protests
While covering the protests — and the Trump administration's out-of-proportion response to them — in Los Angeles on Monday, CNN's national correspondent Jason Carroll was briefly detained by LAPD live on the air without any apparent reason. At one point during the network's live coverage, Carroll could be heard explaining who he is to officers with his hands behind his back. Eventually one officer said, 'We're letting you go. You can't come back. If you come back, you will be arrested.' That at least appears to be a violation of a 2022 California law that specifically protects the rights of journalists to cover protests in areas closed by police. Watch that moment below: Carroll later explained, 'I was walking over to the officer, tried to explain who I was, identified who I was with. He said, I'd like you to turn around. I turned around, I put my hands behind my back. They did not put me in zip ties, but they did grab both my hands as I was escorted over to the side, they said, you are being detained while we lead you out of this area, you are not allowed in this area.' Carroll said he asked, 'am I being arrested, they said 'no you're not being arrested, you're being detained.'' CNN later said two camera operators were arrested outright, though their status isn't known at this time. Other journalists covering the protests in Los Angeles have been injured by law enforcement actions. The situation recalls the George Floyd protests in 2020 which featured several high profile incidents of police attacking journalists. One such attack resulted in a $1 million settlement. The post LAPD Briefly Detains CNN Reporter During Live Coverage of Protests | Video appeared first on TheWrap.
Daily Mail
4 hours ago
- Politics
- Daily Mail
Astonishing moment CNN host realizes reporter is being detained by cops during live segment from LA riots
A CNN reporter and his crew were briefly detained, forced out of an area of the Los Angeles riots and warned by police if he trespassed again he would be arrested. Just after midnight, live coverage of the chaos was briefly interrupted as an anchor Laura Coates could hear someone speaking to police. Jason Carroll, a national correspondent covering the anti-ICE riots in his native California, was on the ground when suddenly he was confronted by law enforcement. Coates interrupted CNN law enforcement and intelligence analyst John Miller: 'Wait one second, John. Hold on. I want to get Jason. What's going on? I hear you. What am I seeing? Jason Carroll being... What? What happened? Jason?' Carroll finally speaks while talking to a member of law enforcement attempting to remove him from the area. 'I am being detained. I am being detained, Laura,' he said to Coates, before turning to the officer and asking: 'I am not being arrested, correct?' One officer can be heard asking if Carroll heard what another officer told him, which the reporter says he could not hear. 'We're letting you go but you can't come back here, because then if you come back in, you go,' suggesting he would be arrested if he returned. Carroll agrees and thanks the officer before telling him to 'take care.' Before the reporter can explain what happened, he is stopped by another journalist who describes himself as being from The New York Times. 'I'm Chris with the New York Times. We got video of you guys, if you need it later,' the second reporter said. Carroll thanks the New York Times employee and then describes what had just happened. 'I was called over, and the officer told me to put my hands behind my back,' he said. Carroll asked the officer if he was being arrested before being told he was merely detained. 'I was walked out of the area. They took down my information,' he added before his audio is lost. A few minutes later, Coates reestablishes contact with Carroll and he gets into more detail. 'They did not put me in zip ties, but they did grab both my hands as I was escorted over to the side,' he said. Carroll described what occurred as one of the 'risks' that the press takes to cover these stories, though he admitted it was 'low on that sort of scale.' 'It is something that I wasn't expecting simply because we've been out here all day,' Carroll said. He noted that typically, officers usually recognize that 'the press is there doing a job.' Carroll then returned to reporting on those who were being arrested for not dispersing from the area. The network later reported that other members of Carroll's crew were also briefly detained and forced to leave the protest zone. Two security personnel for CNN were also detained Monday night but were not charged, they said. Carroll has been with the network for well over a decade. has reached out to CNN for comment. At least 74 people have been arrested in connection with riots of over the weekend with more to come as the chaos continues to rage across the streets of California's biggest city At least 74 people have been arrested in connection with riots of over the weekend with more to come as the chaos continues to rage across the streets of California's biggest city. Hundreds of Marines have been mobilized to Los Angeles after Donald Trump sent National Guard troops to quell the immigration protests. Chaos erupted after protesters clashed with immigration officials across downtown Los Angeles over the weekend, leading to three days of violence and Looters targeted businesses across the city amid the demonstrations, which saw cars torched and security forces firing tear gas at rioters. Despite the National Guard's presence, the military is set to temporarily deploy about 700 Marines from the Marine Corps Air Ground Combat Center in Twentynine Palms to the city. It is unclear what grounds the administration used to send the troops, but for now, the Insurrection Act is not expected to be invoked. California officials have been slammed for their handling of the riots as an understaffed police department struggles to quell the violence. Gov. Gavin Newsom launched a lawsuit against the Trump Administration for unlawfully' deploying another 2,000 National Guard troops. Trump told reporters he would support border czar Tom Homan if he arrested the 'criminal' governor. 'I would do it,' the president said when asked about Newsom daring his administration to arrest him. 'I like Gavin Newsom; he's a nice guy, but he's grossly incompetent, everybody knows it,' the president added.
CNN
5 hours ago
- Politics
- CNN
CNN crew escorted away from protest zone by LAPD
CNN's Jason Carroll and his crew were escorted out of a LA protest zone by police officers. One police officer told the crew to put their hands behind their backs so they could be walked out of the protest zone.
CNN
5 hours ago
- Politics
- CNN
CNN crew escorted away from protest zone by LAPD
CNN's Jason Carroll and his crew were escorted out of a LA protest zone by police officers. One police officer told the crew to put their hands behind their backs so they could be walked out of the protest zone.
News.com.au
06-05-2025
- Health
- News.com.au
Biocurious: With psychedelic therapies gaining cred, Tryptamine offers patients and investors the trip of a lifetime
Tryptamine is focused on using psilocybin to treat difficult mental health and neurological conditions In league with Swinburne University, the company will launch a groundbreaking binge eating disorder trial using intravenous delivery With government and regulatory attitudes rapidly evolving, the company says the first FDA-approved psychedelic treatment is nigh The CEO of local psychedelic drug developer Tryptamine Therapeutics (ASX:TYP), CEO Jason Carroll isn't afraid to make the big call. His bold prediction? The US Food & Drug Administration (FDA) will approve a mind-altering agent for a broad mental health indication by the end of next year, after decades of psychedelics being in the drug-development wilderness. Carroll says several drug developers are close to amassing enough clinical data to front the agency. The Nasdaq-listed Compass Pathways is in phase III trial stage for using psilocybin – a.k.a. 'magic mushrooms' – for treatment-resistant depression (TRD). A read-out is due later this year. 'Compass will have the data buttoned down and I think they will present a good proposal to the FDA,' he says. 'They will produce the data the world wants to see on psilocybin and its efficacy.' Most drug developers don't exactly wish their rivals the best of success, but Carroll says what's good for Compass benefits the whole nascent sector. 'It will help the market to understand there is a viable pathway to approval.' Turn on, tune in and don't drop out In the early 1970s Richard Nixon's war on drugs halted medical research on psychedelics, which had amassed plenty of – er – real-world evidence in the 1960s. Trippy hippies aside, hundreds of formal LSD trials had been carried out since the 1940s. As the protest-era Bob Dylan crooned, the times they are a-changin'. In 2019 the FDA granted psilocybin 'breakthrough' status, enabling potentially fast-track registration. In a February 2023 surprise, the Australian Therapeutic Goods Administration said it would allow authorised psychiatrists to prescribe psilocybin and MDMA (a.k.a. molly or ecstasy). This was to treat TRD and post-traumatic stress disorder (PTSD) respectively. Now, new US health secretary Robert F Kennedy Junior keenly supports advancing psychedelic therapies. Carroll says while the laws are changing, 'the challenge is to bring pharmaceutical rigour to the category'. In effect, the sector needs to transcend the reputation of the microdosing worried well at $1000 a night at Californian wellness retreats, as portrayed by Nicole Kidman's character in Nine Perfect Strangers. 'The world needs to see efficacy data, not just trendy buzzwords,' he says. Make room for the 'shroom Tryptamine's drug of choice – so to speak – is a synthetic version of psilocybin, the active ingredient in magic mushrooms. Psilocybin currently is being researched in no fewer than 25 indications. Tryptamine is targeting three overlooked disorders: binge eating disorder (BED), fibromyalgia and irritable bowel syndrome (IBS). IBS affects about 6-8% of the population, BED 2-3% and fibromyalgia 3-5%. 'These are significant conditions, and they are less discussed from a neurological viewpoint,' Carroll says. Tryptamine has completed phase II studies for BED and fibromyalgia, while an IBS study is ongoing. These trials have used an oral version of the drug, TRP-8802. In a world first, the company is poised to carry out a BED trial using an intravenous (IV) infused version, TRP-8803. TRP-8803 uses the psilocybin metabolite psilocin. IV takes the direct route Carroll says IV delivery is better controlled, with a faster effect because the agent goes directly from bloodstream to brain. While oral delivery is more convenient, IV infusions ensure the products are taken in the right dosage under the right supervision. 'The results are known quickly, whereas with oral delivery it takes one or three hours for an effect,' he says. IV delivery offers practical and commercial benefits, because an oral patient might have to be in the supervised clinic for up to 10 hours. 'If you can treat four or five patients in a day instead of one, it makes a significant difference.' IV delivery also avoids the big variabilities in the level of patient-by-patient responses, which are hit or miss. The BED trial follows an IV safety study in Adelaide last year, enrolling 14 healthy volunteers. Let's put binge eating to BED BED is the most common eating disorder in the US and second most prevalent in Australia. Patients may suffer depression, anxiety, PTSD and compulsive behaviours. Carried out at the University of Florida, the phase 2a TRP-8802 trial showed a mean reduction of more than 80% in binge eating, as well as a 60% reduction in anxiety and 45% decline in depression. This was after a single dose, over three to four months. Tryptamine last month inked a clinical trial research deal with Swinburne University, by which the house of learning carries out the world's first BED trial using the IV-based TRP-8803. Starting in the June quarter, the study entails two six-person cohorts being dosed two weeks apart (accompanied by psychotherapy). Each cohort will receive two doses, either high or mid-range. The trial assesses the safety, feasibility and efficacy of TRP-8803. The company expects top-line results from the open-label study in the December quarter. Fibromyalgia and IBS Suffered by about one million Australians and 10 million Americans, fibromyalgia stems from the brain and manifests itself as pain throughout the body. Doctors often dismiss the condition as 'all in the head' and they are right – but not in the dismissive manner intended. The company's five-patient study was done at the University of Michigan, which specialises in chronic pain. Reported in August last year, the results showed not only reduced pain, but improved sleep and cognitive functions. Meanwhile the trial of the 'neuro-gastric' condition IBS was done at the esteemed Massachusetts General Hospital. Interim results last December showed a 75% pain reduction in the first four of up to 10 patients, as well as a 'meaningful decrease' in anxiety. Tryptamine expects final results by mid 2025. Cashed up and ready to dose Courtesy of a $6 million placement last year, Tryptamine held cash of $4.58 million as of the end of March, with a further R&D tax refund of $900,000 to $1 million to come. Carroll says this will fully fund the study. The placement was backed by luminaries including Dr Daniel Tillett, a medical entrepreneur and the force behind cancer drug developer Race Oncology. Tillett has become a Tryptamine non-executive director. Carroll says Tryptamine is happy to stick with psilocybin, rather than dabble in MDMA, LSD or the ultra-trendy horse tranquilliser ketamine. 'Psilocybin is the gold-standard psychedelic,' he says. 'It's the safest because it's non-addictive with a high dosage needed to make you ill.' Ultimately, psychedelics are not so much about blocking the pain, but re-wiring how the brain works. 'People with depression have a certain way of thinking about themselves and if you break that cycle, they will be much more comfortable with their condition.'
